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There are many ways to perform noninvasive testing in pa-
tients with coronary artery disease (CAD), including myocar-
dial perfusion imaging with single-photon emission computed
tomography (SPECT), positron-emission tomography (PET),
and coronary computed tomography angiography (CTA).
Results from series of patients evaluated with single modali-
ties have already been published by many researchers [1–3],
but there are few head-to-head comparisons of the outcomes
of alternative test strategies [4, 5]. Consequently, the compar-
ative effectiveness of different noninvasive cardiac testing
strategies has been difficult to assess.
The recently published SPARC registry (Study of
Myocardial Perfusion and Coronary Anatomy Imaging
Roles in Coronary Artery Disease) in JACC by the group of
DiCarli et al. (Stanford, CA, USA) was a multicentre study
designed to collect standardised clinical data on patients un-
dergoing CTA, PET, or SPECT [6]. The primary purpose of
the SPARC study was to evaluate the economic outcomes of
using CTA, PET, or SPECT to evaluate patients with
suspected CAD. The authors used an observational registry
of 1703 patients: 590 patients underwent CTA, 548 patients
had PET and 565 patients SPECT for diagnosis of suspected
CAD. Patients were followed for 2 years; documented re-
source use, medical costs for CAD, and clinical outcomes
were assessed.
The main findings were that costs were significantly lower
for SPECT compared with CTA or PET in the evaluation of
suspected CAD. SPECT was economically attractive com-
pared with PET, whereas CTA was associated with higher
costs and no significant difference in mortality compared with
SPECT. More specifically, the authors observed that patients
who underwent coronary CTA and PET experienced higher
rates of subsequent invasive coronary arteriography (16% and
15%, respectively) as compared with patients who underwent
SPECT (7 %). The mean total radiation was significantly
higher for CTA (15.1 mSV) compared with SPECT (11.7
mSV), both for the initial tests (13 mSV vs. 11 mSV) and
for follow-up tests and procedures (2.1 mSV vs. 0.7 mSV).
Exposure from follow-up tests and procedures was higher
after PET (2.0 mSV) than after SPECT (0.6 mSV).
The findings in favour of SPECTare in line with a decision
model by Garber and Solomon [7], who compared exercise
treadmill testing, stress echocardiography, planar thallium
imaging, SPECT, and PET imaging with a strategy of imme-
diate invasive angiography. They found SPECT to be much
more cost-effective than PET for noninvasive diagnosis, and
SPECT to be a better option than immediate invasive coronary
angiography. In terms of outcomes, Shaw et al. [1] found that
patients who underwent initial SPECT with selective cardiac
catheterisation had lower costs than patients who underwent
routine coronary angiography (END study). In the EMPIRE
study by Underwood et al. [2] it was demonstrated that strat-
egies using myocardial perfusion imaging were cheaper and
equally effective when compared with strategies that did not
use myocardial perfusion imaging, both for the cost of diag-
nosis and for overall 2-year management costs; the 2-year
patient outcome was the same. Sharples et al. [8] randomised
898 patients to SPECT, stress echocardiography, magnetic
resonance imaging (MRI), or direct invasive coronary angi-
ography, and found SPECT to be as useful as immediate
invasive angiography with similar costs. A limitation of the
SPARC study is the fact that MRI was not included in the
comparative strategies. In addition, as the study started in
2006, in recent years many technological revolutions have
taken place for all imaging modalities indicating that studies
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such as SPARC should be repeated and extended every 5–
10 years [9].
Analysis of the current SPARC registry at least suggests
that SPECT is the noninvasive imaging procedure of choice to
evaluate patients with suspected CAD in terms of subsequent
medical costs. SPECToffered the lowest costs over 2 years of
follow-up among patients with suspected CAD. The signifi-
cantly higher costs among patients undergoing CTA or PET
were primarily due to higher rates of subsequent invasive
cardiac procedures, because there was little difference in ini-
tial costs of testing.
To conclude, the use of SPECT myocardial perfusion im-
aging was associated with lower costs over 2 years of follow-
up than the use of CTA or PET, primarily because of fewer
subsequent invasive procedures. Consequently, SPECT imag-
ing seems to be the preferred imaging strategy in patients with
suspected CAD. The value of SPECT imaging has been
underscored by several recent reports [10–13]. However, larg-
er and more definitive studies, such as the ongoing PROMISE
(Prospective Multicenter Imaging Study for Evaluation of
Chest Pain) trial (NCT01174550), are needed to assess the
value and cost effectiveness of the various noninvasive imag-
ing strategies.
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